Not Signed In -
Dental Health |
Dental/ Oral Health |
Clinical Trial: A Protocol for the Use of Chlorhexidine Gluconate Saturation for the Reduction of Dental Biofilm Formation on Polymethylmethacrylate Restoration
This study is not yet open for patient recruitment.
Verified by Hadassah Medical Organization November 2005
|
Purpose
Chlorhexidine gluconate (CHX), as an anti plaque agent, is commonly used with a variety of products. In this study we, the investigators at Hadassah Medical Organization, intend to examine the efficacy of a single dip in CHX of provisional restoration prior to oral cementation. If the protocol is effective, we intend to calibrate it and recommend clinical use of the protocol. The examination of biofilm formation will be both with electron microscope and confocal scanning laser microscope.
| Condition | Intervention | Phase |
|---|---|---|
| Dental Plaque | Procedure: saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation | Phase I |
MedlinePlus related topics: Tooth Disorders
Study Type: Interventional
Study Design: Prevention, Non-Randomized, Single Blind, Uncontrolled, Single Group Assignment, Pharmacokinetics Study
Official Title: Examination of the Immersion of Provisional Crown Material in Chlorhexidine Gluconate on Dental Plaque Formation in Vivo
Further study details as provided by Hadassah Medical Organization:
Primary Outcomes: calibration of a preventative protocol for biofilm formation measured by confocal scanning laser microscope and scanning electron microscope
Expected Total Enrollment: 12
Expected Total Enrollment: 12
Study start: December 2005
Eligibility
Genders Eligible for Study: Both
Accepts Healthy Volunteers
Criteria
Inclusion Criteria:
- Any volunteer without systemic condition
Exclusion Criteria:
- Intake of antibiotic drug three months prior to experiment
Location and Contact Information
Please refer to this study by ClinicalTrials.gov identifier NCT00259181
Arik Tzukert, DMD 00 972 2 6776095 arik@hadassah.org.il
Hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il
Hadas Lemberg, PhD 00 972 2 6777572 lhadas@hadassah.org.il
Israel
Hadassah Medical Organization, Jerusalem, 91120, Israel
Michael M Perez Davidi, DMD, Principal Investigator
Study chairs or principal investigators
Michael M Perez Davidi, DMD, Study Director, Hadassah Medical Organization
More Information
Study ID Numbers: 191058HMO-CTIL
Last Updated: December 8, 2005
Record first received: November 24, 2005
ClinicalTrials.gov Identifier: NCT00259181
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
ClinicalTrials.gov processed this record on 2006-01-10
Last Updated: December 8, 2005
Record first received: November 24, 2005
ClinicalTrials.gov Identifier: NCT00259181
Health Authority: Israel: Israeli Health Ministry Pharmaceutical Administration
ClinicalTrials.gov processed this record on 2006-01-10
email this page
print this page
bookmark this page
feedback on this page
